Hansoh Pharmaceutical : 2024环境、社会及管治报告

ENVIRONMENTAL, SOCIAL AND COVERNANCE REPORT

（lncorporated in the Cayman lslands with limited liability）

CONTENTS

ABOUT THE REPORT 03

1. CHAIRLADY'S STATEMENT 05

2. ABOUT HANSOH PHARMA 07

3. 2024 PERFORMANCE HIGHLIGHTS 08

   1. RESPONSIBILITY FOOTPRINT 08

   2. DATA PERFORMANCE 09

   3. ESG-RELATED HONORS AND AWARDS 11

      1. BUSINESS ETHICS 30

         1. GOVERNANCE OF BUSINESS ETHICS 31

         2. BUSINESS ETHICS STRATEGY 35

         3. MANAGEMENT OF BUSINESS ETHICS RISKS 43

         4. ETHICAL PERFORMANCE 46

4. CORPORATE GOVERNANCE 12 6. ADDRESSING CLIMATE CHANGE 47

   1. BOARD STATEMENT 13

   2. ESG GOVERNANCE 14

   3. COMMUNICATION WITH STAKEHOLDERS 19

   4. MATERIAL ISSUES 21

   5. RISK MONITORING 24

1. CLIMATE GOVERNANCE FRAMEWORK 48

2. IDENTIFICATION AND ASSESSMENT OF 51

   CLIMATE RISKS

3. CLIMATE TRANSITION STRATEGY DRIVEN 55

   BY CARBON NEUTRALITY GOALS

4. PROGRESS AND PERFORMANCE OF 59

CLIMATE TARGET QUANTIFICATION

7. ENVIRONMENTAL FRIENDLY	61		10. TALENT DEVELOPMENT	120
7.1 ENVIRONMENTAL GOVERNANCE	62		1O.1 TALENT AND ORGANIZATIONAL GOVERNANCE	121
7.2 ENVIRONMENTAL STRATEGY	63	1O.2 TALENT MANAGEMENT SYSTEM		124

1. ENVIRONMENTAL RISK MANAGEMENT 65

   THROUGHOUT THE EMPLOYEE LIFECYCLE 1O.3 HUMAN RESOURCES RISK MANAGEMENT 134

2. PRACTICE AND ACTION 68

3. ENVIRONMENTAL PERFORMANCE 8O

1O.4 TALENT DEVELOPMENT PERFORMANCE

1O.5 SPECIAL TOPIC

142

145

8. PRODUCT QUALITY	83		11. ACCESS TO HEALTHCARE	149
8.1 QUALITY GOVERNANCE	84		11.1 GOVERNANCE AND STRATEGY	15O
8.2 QUALITY STRATEGY	85		11.2 ACTIONS AND PRACTICES	153
8.3 QUALITY RISK MANAGEMENT	89		11.3 PERFORMANCE INDICATORS	163
8.4 PRACTICE AND ACTION	92		11.4 SPECIAL CASE	166

8.5 QUALITY MANAGEMENT PERFORMANCE

1O2

1. SUSTAINABLE SUPPLY CHAIN 103 APPENDIX 171

   1. SUPPLY CHAIN GOVERNANCE

   2. SUSTAINABLE PROCUREMENT STRATEGY

   3. SUPPLY CHAIN RISK MANAGEMENT

   4. SUPPLY CHAIN COLLABORATION

   5. SUPPLY CHAIN MANAGEMENT PERFORMANCE

1O4

1O7

11O

113

117

ESG REPORT ASSURANCE STATEMENT

193

ABOUT THE REPORT

The Repo爀琀 is the sixth Environmental, Social and Governance ("ESG") Repo爀琀 of Hansoh Pharmaceutical Group Company Limited (the "Company") upon its listing. It systematically elaborates on ESG governance, strategies, risks, goals and pe爀昀ormance of the Company and its subsidiaries (the "Group" "Hansoh Pharma" "We") in 2024 and focuses on addressing material issues of concern to stakeholders.

TIME OF THE REPORT

The information and data in the Repo爀琀 cover the period from Janua爀礀 1, 2024 to December 31, 2024 ("Repo爀琀ing Period"), unless otherwise speci昀椀ed.

SCOPE

OF THE REPORT

The disclosure scope of the substantive content of social and governance in the Repo爀琀 is consistent with that in the 2024 Annual Repo爀琀. Given the subsidiaries of the Company, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司) ("Jiangsu Hansoh"), Changzhou Hansoh Pharmaceutical Group Co., Ltd. (常州恒邦藥業有限公司) ("Changzhou Hansoh") and Shanghai Hansoh Biomedical Co., Ltd. (上海翰森生物醫藥科技有限公司) ("Shanghai Hansoh") accounted for over 90% of the Group's operating revenue in 2024, they are major operating entities of the Group, and also major environmental impact companies. On the principle of materiality, the substantive content of the environment section in the Repo爀琀 mainly focuses on these three subsidiaries mentioned above, unless there are special circumstances.

STANDARD OF REFERENCE

The Repo爀琀 is compiled based on the Environmental, Social and Governance Repo爀琀ing Code (《環境、社會及管治報告守則》) (the "ESG Code") as set out in Appendix C2 to the Listing Rules of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The Repo爀琀 refers to the Global Repo爀琀ing Initiative (GRI)'s Standards for Sustainable Repo爀琀ing (可持續報告標準) and the International Financial Repo爀琀ing Standards' Sustainability Disclosure Standard (IFRS Sustainability Disclosure Standard). It is also in alignment with the United Nations Sustainable Development Goals (SDGs), and the concerned issues of the Morgan Stanley Capital International (MSCI) ESG rating and the S&P Global Corporate Sustainability Assessment (CSA).

REPORTING PRINCIPLE

The Repo爀琀 adheres to the four principles outlined in the ESG Code of the Stock Exchange, which are "Materiality", "Quantitative", "Balance" and "Consistency".

Materiality

The Company conducted daily communication and speci昀椀c su爀瘀eys with stakeholders to collect and analyze ESG issues which are the most pressing issues of various pa爀琀ies, and the most impo爀琀ant ones of the Company. We used this information to determine the focus of the Repo爀琀. The process of identifying stakeholders, communication, and establishing these issues will be detailed in the Section

4.4 - Material Issues.

Quantitative

To help stakeholders clearly and accurately understand the Company's ESG pe爀昀ormance, we will disclose the standards, methods, assumptions, calculation tools, conversion factor sources, and other information used in the quanti昀椀cation of emissions, energy consumption, and other related data.

Consistency

Any modi昀椀cations made to the statistical scope, statistical methods, conversion factors, etc., during the Repo爀琀ing Period and scope as boundaries stated above will be described with the basis in the corresponding sections of the Repo爀琀. This approach will enable stakeholders to gain a comprehensive and unbiased understanding of the Company's advancements and contributions towards ESG aspects.

Balance

The Repo爀琀 presents a complete and balanced picture of the Group's ESG information.

DATA SOURCES

The data and cases presented in the Repo爀琀 are obtained from the Company's production and operational records, documents available to the public, and public repo爀琀s from governments and news media. There are no deliberately false records or misleading statements. The Company takes responsibility for ensuring that the information sources are authentic, accurate, and complete. The moneta爀礀 unit used throughout the Repo爀琀 is RMB, unless otherwise speci昀椀ed.

ACCESS TO THE REPORT

The Repo爀琀 is prepared in Traditional Chinese and English, and will be published on the websites of the Company (https://www.hspharm.com) and the Stock Exchange (https://www.hkexnews.hk). For any suggestion and comment on the Repo爀琀, please contact us at the email address: [e-mail]

CONFIRMATION AND APPROVAL

The Repo爀琀 is con昀椀rmed by the management of the Company and independently veri昀椀ed by the China Quality Ce爀琀i昀椀cation Center, and is approved by the Board of Directors of the Company on April 28, 2025.